HPV vaccination
HPV vaccination
Overview
Human papillomavirus (HPV) vaccination is a preventive immunotherapy strategy designed to protect against infection by oncogenic strains of human papilloma virus, a sexually transmitted pathogen responsible for the majority of cervical cancers, as well as oropharyngeal, anal, vulvar, vaginal, and penile malignancies. Currently licensed vaccines — including the bivalent, quadrivalent, and nonavalent formulations — elicit robust humoral immune responses targeting the L1 capsid proteins of high-risk HPV (hrHPV) genotypes, most critically HPV-16 and HPV-18, which together account for approximately 70% of cervical cancer cases. By generating high-titer neutralizing antibodies prior to initial exposure, vaccination prevents viral integration into host epithelial cell DNA, thereby interrupting the carcinogenic cascade that — through mechanisms including oncogene-driven cellular senescence bypass — ultimately leads to recurrent cervical cancer and other HPV-associated malignancies.
Vaccination programs are generally recommended for adolescents before sexual debut, though catch-up schedules extend eligibility into early adulthood. Despite decades of safety and efficacy data, global uptake remains heterogeneous, shaped by healthcare infrastructure, socioeconomic factors, cultural attitudes, and policy environments. Population-level evidence from organized cervical screening programs has increasingly demonstrated real-world reductions in hrHPV prevalence and precancerous lesions among vaccinated cohorts, underscoring the public health imperative of achieving high and equitable coverage.
Recent Publications Focus
Below is a summary of the newest research publications targeting HPV vaccination (sorted by publication date).
Recent research has highlighted evolving approaches to HPV vaccination implementation across diverse populations and settings. In 2019, the U.S. Advisory Committee on immunization Practices updated recommendations for mid-adult HPV vaccination (ages 27-45 years), transitioning from routine recommendations to a shared clinical decision-making (SCDM) approach [PMID 42417053]. This shift has introduced implementation challenges, as some aspects of the guidance are vague or inconsistent with established SCDM principles, potentially leading to confusion among healthcare providers and suboptimal vaccination rates [PMID 42417053]. Vaccine uptake remains suboptimal across multiple populations. Among healthcare workers, only 41.6% reported prior HPV vaccination despite potential occupational exposure to HPV [PMID 42189578]. Notably, vaccine uptake among healthcare workers was strongly associated with age, with those aged 27-45 years showing significantly higher rates than those over 45 years, while willingness to recommend vaccination was primarily driven by confidence in vaccine safety rather than HPV knowledge [PMID 42189578]. Similar barriers to vaccination have been documented in other populations, such as young girls in Morocco, where hesitancy and adoption challenges persist despite the vaccine's proven effectiveness in reducing cervical cancer incidence [PMID 42160355].
Population-based studies provide encouraging evidence for the real-world protective impact of HPV vaccination programs. In Italy, women who received two or more doses of HPV vaccine showed dramatically reduced infection prevalence with vaccine-targeted genotypes HPV16/18 compared to unvaccinated women [PMID 42084786]. Analysis of nationally representative U.S. data found that vaccine-targeted oral HPV infection prevalence was 1.9% overall among adults aged 18-64 years, but unvaccinated individuals in the vaccine-eligible age group (18-26 years) had significantly higher odds of oral HPV infection than vaccinated peers [PMID 42080318]. These findings underscore the protective benefits of vaccination, though disparities in vaccination coverage persist across demographic and geographic populations [PMID 42080318].
Targeted institutional and community-based vaccination strategies are emerging as effective mechanisms to improve coverage and address barriers. In France, a school-based educational program was associated with improved HPV vaccination uptake among students aged 11-13 years, with enhanced information delivery helping to address parental vaccine hesitancy [PMID 42044612]. Additionally, quality improvement initiatives have demonstrated the feasibility of offering adjuvant HPV vaccination at the time of loop electrosurgical excision procedure (LEEP) in colposcopy settings, with the goal of reducing cervical intraepithelial neoplasia 2+ recurrence in high-risk patients [PMID 41825633]. Healthcare settings serving women seeking abortion have been identified as underutilized opportunities for catch-up HPV vaccination and cervical screening, potentially reaching populations with limited engagement in routine prevention services [PMID 41224642].